Recent Insider Transactions Derivative • Jul 21
Co-Founder & Executive Chairman notifies of intention to sell stock Jurgi Camblong intends to sell 24k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$5.87, it would amount to US$143k. Jurgi currently holds 3.53m shares (0.042107524875122274 of the company). Company insiders have collectively sold US$175k more than they bought, via options and on-market transactions in the last 12 months. Duyuru • Jul 21
SOPHiA GENETICS SA to Report Q2, 2026 Results on Aug 04, 2026 SOPHiA GENETICS SA announced that they will report Q2, 2026 results on Aug 04, 2026 Price Target Changed • Jul 20
Price target increased by 17% to US$9.00 Up from US$7.67, the current price target is an average from 4 analysts. New target price is 42% above last closing price of US$6.33. Stock is up 81% over the past year. The company is forecast to post a net loss per share of US$0.84 next year compared to a net loss per share of US$1.17 last year. Recent Insider Transactions Derivative • Jul 01
Co-Founder & Executive Chairman notifies of intention to sell stock Jurgi Camblong intends to sell 70k shares in the next 90 days after lodging an Intent To Sell Form on the 30th of June. If the sale is conducted around the recent share price of US$5.98, it would amount to US$419k. Jurgi currently holds 3.62m shares (0.04316089777938126 of the company). Company insiders have collectively bought US$10k more than they sold, via options and on-market transactions, in the last 12 months. Duyuru • Jun 22
SOPHiA GENETICS SA Approves Board Changes SOPHiA GENETICS SA announced that at the annual general meeting held on June 18, 2026 approved that co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective July 1, 2026. New Risk • Jun 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$27m net loss in 3 years). Shareholders have been diluted in the past year (23% increase in shares outstanding). Recent Insider Transactions • Jun 07
Executive VP & CFO recently bought US$99k worth of stock On the 5th of June, George Cardoza bought around 20k shares on-market at roughly US$4.95 per share. This transaction amounted to 6.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was George's only on-market trade for the last 12 months. Recent Insider Transactions Derivative • May 20
Executive VP notifies of intention to sell stock Philippe Menu intends to sell 16k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of May. If the sale is conducted around the recent share price of US$4.69, it would amount to US$73k. Since March 2026, Philippe's direct individual holding has increased from 173.62k shares to 256.39k. Company insiders have collectively sold US$3.4k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • May 06
First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2026 results: US$0.27 loss per share (further deteriorated from US$0.26 loss in 1Q 2025). Revenue: US$21.7m (up 22% from 1Q 2025). Net loss: US$19.3m (loss widened 11% from 1Q 2025). Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) missed analyst estimates by 11%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year. Duyuru • May 06
SOPHiA GENETICS SA Reaffirms Earnings Guidance for the Fiscal Year 2026 SOPHiA GENETICS SA reaffirmed earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth compared to the fiscal year 2025. Duyuru • Apr 21
SOPHiA GENETICS SA to Report Q1, 2026 Results on May 05, 2026 SOPHiA GENETICS SA announced that they will report Q1, 2026 results Pre-Market on May 05, 2026 Reported Earnings • Mar 04
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: US$1.17 loss per share (further deteriorated from US$0.95 loss in FY 2024). Revenue: US$77.3m (up 19% from FY 2024). Net loss: US$79.0m (loss widened 26% from FY 2024). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) missed analyst estimates by 2.0%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 11% per year. Duyuru • Mar 03
SOPHiA GENETICS SA Reaffirms Earnings Guidance for the Fiscal Year 2026 SOPHiA GENETICS SA reaffirmed earnings guidance for the fiscal year 2026. For the year, the company expects revenue to be between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth compared to the fiscal year 2025. Price Target Changed • Jan 26
Price target increased by 9.5% to US$7.67 Up from US$7.00, the current price target is an average from 3 analysts. New target price is 44% above last closing price of US$5.32. Stock is up 19% over the past year. The company is forecast to post a net loss per share of US$1.15 next year compared to a net loss per share of US$0.95 last year. Duyuru • Jan 12
SOPHiA GENETICS SA to Report Q4, 2025 Results on Mar 03, 2026 SOPHiA GENETICS SA announced that they will report Q4, 2025 results on Mar 03, 2026 Recent Insider Transactions Derivative • Dec 31
Co-Founder notifies of intention to sell stock Jurgi Camblong intends to sell 30k shares in the next 90 days after lodging an Intent To Sell Form on the 29th of December. If the sale is conducted around the recent share price of US$4.73, it would amount to US$142k. Since March 2025, Jurgi has owned 2.65m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Recent Insider Transactions Derivative • Nov 12
Co-Founder notifies of intention to sell stock Jurgi Camblong intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of November. If the sale is conducted around the recent share price of US$4.37, it would amount to US$108k. Since March 2025, Jurgi has owned 2.65m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Duyuru • Nov 05
SOPHiA GENETICS SA Revises Earnings Guidance for the Year 2025 SOPHiA GENETICS SA revised earnings guidance for the Year 2025. For the period, full year revenue is now expected to be in the range of $75 to $77 million, representing year-over-year growth of 15% to 18%. This compares to the prior range of $72 to $76 million. Reported Earnings • Nov 05
Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2025 results: US$0.30 loss per share (further deteriorated from US$0.28 loss in 3Q 2024). Revenue: US$19.5m (up 23% from 3Q 2024). Net loss: US$20.0m (loss widened 8.6% from 3Q 2024). Revenue exceeded analyst estimates by 7.4%. Earnings per share (EPS) missed analyst estimates by 24%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Oct 21
SOPHiA GENETICS SA to Report Q3, 2025 Results on Nov 04, 2025 SOPHiA GENETICS SA announced that they will report Q3, 2025 results Pre-Market on Nov 04, 2025 New Risk • Sep 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$31m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Recent Insider Transactions Derivative • Sep 24
Independent Non-Executive Director notifies of intention to sell stock Vincent Ossipow intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 23rd of September. If the sale is conducted around the recent share price of US$3.93, it would amount to US$83k. Since March 2025, Vincent has owned 443.81k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Recent Insider Transactions Derivative • Aug 20
Co-Founder notifies of intention to sell stock Jurgi Camblong intends to sell 41k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of August. If the sale is conducted around the recent share price of US$3.49, it would amount to US$142k. Since March 2025, Jurgi has owned 2.65m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Major Estimate Revision • Aug 12
Consensus EPS estimates fall by 12% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$0.96 to -US$1.08 per share. Revenue forecast unchanged at US$74.5m. Healthcare Services industry in the US expected to see average net income growth of 22% next year. Consensus price target down from US$7.25 to US$7.00. Share price fell 8.2% to US$3.14 over the past week. Duyuru • Aug 06
SOPHiA GENETICS SA has filed a Follow-on Equity Offering in the amount of $50 million. SOPHiA GENETICS SA has filed a Follow-on Equity Offering in the amount of $50 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Transaction Features: At the Market Offering Reported Earnings • Aug 05
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2025 results: US$0.33 loss per share (further deteriorated from US$0.23 loss in 2Q 2024). Revenue: US$18.3m (up 16% from 2Q 2024). Net loss: US$22.4m (loss widened 48% from 2Q 2024). Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) missed analyst estimates by 38%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Duyuru • Aug 05
SOPHiA GENETICS SA Reiterates Earnings Guidance for the Year 2025 SOPHiA GENETICS SA reiterated earnings guidance for the year 2025. The company reiterated full-year guidance of revenue between $72 million and $76 million. Duyuru • Jul 22
SOPHiA GENETICS SA to Report Q2, 2025 Results on Aug 05, 2025 SOPHiA GENETICS SA announced that they will report Q2, 2025 results Pre-Market on Aug 05, 2025 Recent Insider Transactions Derivative • Jun 22
Independent Non-Executive Director notifies of intention to sell stock Vincent Ossipow intends to sell 18k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of June. If the sale is conducted around the recent share price of US$3.04, it would amount to US$56k. Since March 2025, Vincent has owned 443.81k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Recent Insider Transactions Derivative • May 20
Co-Founder notifies of intention to sell stock Jurgi Camblong intends to sell 43k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of May. If the sale is conducted around the recent share price of US$2.96, it would amount to US$128k. Since March 2025, Jurgi has owned 2.65m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Duyuru • May 10
SOPHiA GENETICS SA, Annual General Meeting, Jun 18, 2025 SOPHiA GENETICS SA, Annual General Meeting, Jun 18, 2025, at 14:00 W. Europe Standard Time. Location: la piece 12, 1180 rolle/vd, Switzerland Reported Earnings • May 08
First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2025 results: US$0.26 loss per share (further deteriorated from US$0.21 loss in 1Q 2024). Revenue: US$17.8m (up 13% from 1Q 2024). Net loss: US$17.4m (loss widened 27% from 1Q 2024). Revenue exceeded analyst estimates by 6.1%. Earnings per share (EPS) missed analyst estimates by 5.7%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Duyuru • May 06
SOPHiA GENETICS SA Provides Reiterates Guidance for the Year 2025 SOPHiA GENETICS SA provided reiterated guidance for the year 2025. Full-year revenue between $72 million and $76 million, representing growth of approximately 10% to 17% compared to full year of 2024. Duyuru • Apr 22
SOPHiA GENETICS SA to Report Q1, 2025 Results on May 06, 2025 SOPHiA GENETICS SA announced that they will report Q1, 2025 results Pre-Market on May 06, 2025 Reported Earnings • Mar 04
Full year 2024 earnings: Revenues and EPS in line with analyst expectations Full year 2024 results: US$0.95 loss per share (improved from US$1.22 loss in FY 2023). Revenue: US$65.2m (up 4.5% from FY 2023). Net loss: US$62.5m (loss narrowed 21% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. Duyuru • Mar 04
SOPHiA GENETICS SA Provides Earnings Guidance for the Year 2025 SOPHiA GENETICS SA provided earnings guidance for the year 2025. Full-year revenue between $72 million and $76 million, representing growth of approximately 10% to 17% compared to full year of 2024. Recent Insider Transactions Derivative • Feb 20
Co-Founder notifies of intention to sell stock Jurgi Camblong intends to sell 90k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of February. If the sale is conducted around the recent share price of US$4.46, it would amount to US$404k. Jurgi currently holds 2.46m shares (0.037027890189429806 of the company). There have been no trades via on-market transactions or options from company insiders in the last 12 months. Duyuru • Feb 18
SOPHiA GENETICS SA to Report Q4, 2024 Results on Mar 04, 2025 SOPHiA GENETICS SA announced that they will report Q4, 2024 results Pre-Market on Mar 04, 2025 Duyuru • Jan 29
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities SOPHiA GENETICS has unveiled the OncoPortal™ Mutation Tracker — a longitudinal MRD tracking tool designed for disease monitoring in the context of oncology. This innovation underscores SOPHiA GENETICS' commitment to advancing data-driven approaches for improved oncology insights. Tracking genomic variants across multiple time points in the same patient is becoming increasingly critical in cancer care, particularly for identifying treatment resistance or detecting residual cancer cells, such as in Measurable Residual Disease (MRD) management. The integration of longitudinal tracking capabilities with next-generation sequencing (NGS) allow the parallel detection of cancer-specific genetic mutations at very low frequencies. This combined approach enables early identification of residual disease or emerging variants, providing a more precise assessment of disease burden, better stratification of high-risk patients, and the ability to tailor treatments to the cancer's unique genomic profile. The OncoPortal™ Mutation Tracker augments the SOPHiA DDM™ Platform's core analytical capabilities to allow clinical researchers to longitudinally monitor evolving genomic variants across multiple time points, providing a comprehensive view of disease evolution. The OncoPortal™ Mutation Tracker enhances workflow efficiency for longitudinal variant tracking by offering flexible low frequency variant selection, customizable threshold settings, and reporting features to generate longitudinal graphical representations, simplifying the process of tracking and analyzing genetic changes over time. Recent Insider Transactions Derivative • Jan 26
Co-Founder notifies of intention to sell stock Jurgi Camblong intends to sell 19k shares in the next 90 days after lodging an Intent To Sell Form on the 24th of January. If the sale is conducted around the recent share price of US$4.33, it would amount to US$81k. Since March 2024, Jurgi has owned 2.46m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. New Risk • Jan 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$43m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Recent Insider Transactions Derivative • Dec 27
Co-Founder notifies of intention to sell stock Jurgi Camblong intends to sell 40k shares in the next 90 days after lodging an Intent To Sell Form on the 24th of December. If the sale is conducted around the recent share price of US$3.31, it would amount to US$134k. Since March 2024, Jurgi has owned 2.46m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. New Risk • Nov 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$39m net loss in 3 years). Share price has been volatile over the past 3 months (9.9% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Duyuru • Nov 06
SOPHiA GENETICS SA Announces Chief Financial Officer Changes SOPHiA GENETICS SA announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi Camblong. He will continue to lead the company's go-to-market function, including Clinical sales, BioPharma Dx sales, sales support, marketing, customer experience, and operations. Ross joined SOPHiA GENETICS in February 2021 as CFO and was appointed as CFO and COO in March 2023. As CFO, Cardoza will oversee all corporate finance functions, including accounting, financial planning and analysis ("FP&A"), investor relations, internal audit, tax, and treasury. Mr. Cardoza brings more than 30 years of experience in the precision medicine and clinical diagnostics industry, with extensive experience in both financial and operational leadership. Before joining SOPHiA GENETICS, he was the CFO and Head of Service Delivery at Biocartis. Prior, he spent over twelve years with NeoGenomics Laboratories in several executive roles (CFO, President Pharma Services Division, and President and Chief Operating Officer Laboratory Operations), and previously spent more than fourteen years with Quest Diagnostics in various roles including Controller of the Central Region. Throughout his career, Cardoza has shown a strong talent for financial management, strategic planning, and driving businesses towards increasing levels of performance. He has a deep understanding of the industry landscape and a proven track record of success in executing and influencing growth-oriented business strategies. Mr. Cardoza holds a B.S. in Finance and Accounting from Syracuse University and an MBA from Michigan State University. Reported Earnings • Nov 05
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: US$0.28 loss per share (further deteriorated from US$0.21 loss in 3Q 2023). Revenue: US$15.9m (down 2.8% from 3Q 2023). Net loss: US$18.4m (loss widened 33% from 3Q 2023). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Duyuru • Nov 05
SOPHiA GENETICS Re-Affirms Earnings Guidance for the Year 2024 SOPHiA GENETICS re-affirmed earnings guidance for the year 2024. For the year, the company expects revenue to be between $65 million and $67 million, representing growth of 4% to 7% compared to Fiscal Year 2023. Duyuru • Oct 23
SOPHiA GENETICS SA to Report Q3, 2024 Results on Nov 05, 2024 SOPHiA GENETICS SA announced that they will report Q3, 2024 results Pre-Market on Nov 05, 2024 Recent Insider Transactions Derivative • Oct 06
Co-Founder notifies of intention to sell stock Jurgi Camblong intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of October. If the sale is conducted around the recent share price of US$3.24, it would amount to US$70k. Since March 2024, Jurgi has owned 2.46m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Duyuru • Sep 16
SOPHiA GENETICS Presents Multimodal Research on AI-Driven Patient Stratification at ESMO 2024 SOPHiA GENETICS will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy. The research is a retrospective, multimodal analysis of the POSEIDON Phase 3 clinical trial (NCT03164616). This trial originally demonstrated that the combination of tremelimumab, durvalumab, and chemotherapy significantly increases progression-free survival (PFS) and overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, which lead to approval of this regiment globally in 1L mNSCLC. The SOPHiA GENETICS study used cutting-edge multimodal machine learning models to analyze clinical, biological, genomic, and imaging data, pinpointing patient subgroups who are most likely to benefit from the combination treatment. The research highlighted signatures identifying patients with non-squamous metastatic NSCLC who may derive higher OS benefit from the addition of tremelimumab to durvalumab plus chemotherapy in the first-line treatment setting. In particular, EGFR wild-type, FGFR3 wild-type, CDKN2A wild-type, KRAS mutation, and STK11 mutation comprised elements of a signature was identified as being associated with a higher OS benefit. These findings could have significant implications for the treatment of NSCLC, as it provides an exploration avenue towards a more tailored approach to patient care. The study will be presented as a poster by Ferdinandos Skoulidis, Department of Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center at ESMO 2024 hosted in Barcelona, Spain from September 13-17, 2024. His presentation showcases the operational feasibility and clinical impact of large-scale multimodal analyses in identifying heterogeneous treatment effects in oncology. Recent Insider Transactions Derivative • Sep 11
Independent Non-Executive Director notifies of intention to sell stock Kathy Hibbs intends to sell 16k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of September. If the sale is conducted around the recent share price of US$3.75, it would amount to US$60k. Since March 2024, Kathy has owned 37.41k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Duyuru • Sep 04
SOPHiA GENETICS SA Unveils New Generation of the Sophia Ddmtm Platform At Morgan Stanley Healthcare Conference 2024 SOPHiA GENETICS launched the new generation of the SOPHiA DDMTM Platform. The new-gen SOPHiA DDMTM Platform offers a new architecture designed to more efficiently compute large amounts of data at-scale, while elevating customer experience with integrated access to multimodal analytics modules. As cancer cases continue to rise across the globe, understanding of the disease becomes more nuanced. Newer, more effective therapies are being developed each day, and data is becoming increasingly critical in diagnosis, therapy selection, and drug development. Since launching the first generation of SOPHiA DDM TM in 2015, the Platform has been at the forefront of these innovations, accelerating the practice of data driven medicine globally as a leading platform in healthcare for using data to improve patient care. Data computed daily by the Platform has surged over the years with over 1.8 million genomic profiles being analyzed on the platform, at a rate of almost 30,000 analyses per month. As the volume and utility of data grows, SOPHiA GENETICS continues to accelerate innovation in the field of data-driven medicine by unveiling best-in-class technology and data science capabilities. The new generation SOPHiA DDM TM Platform offers a new, web-based architecture, which allows the Platform to compute and process data more efficiently by leveraging microservices as well as the newest technologies in cloud computing and GPUs from partners such as NVIDIA and Microsoft.
Faster data processing not only optimizes computing, but it also provides answers more rapidly. Customers will experience faster turnaround time from data upload to insights. In addition, more efficient data processing capabilities enable the launch of new capabilities, such as the new whole genome sequencing (WGS) application being released later this year. It also enables new capabilities in multimodal analytics, which require processing of more complex and sizeable data sets across data modalities. Under the new generation of SOPHiA DDMTM, genomic, radiomic, and multimodal analytics capabilities will be offered in a single, integrated workspace. Customers benefit from the three analytics modules by selecting applications that best suit their needs:
Genomics: Ingests genomics FASTQ and VCF data to efficiently call, annotate, and pre-classify oncogenic or pathogenic variants. Radiomics: Processes data from various imaging modalities (e.g., CT scans, PET-CT, MRI), segments anatomical areas of interest, and extracts radiomic features for further analysis. Multimodal: Aggregates data from the radiomics and genomics modules, along with processed clinical, biological, and histological data, to train and verify predictive models at the individual patient level. Major Estimate Revision • Aug 13
Consensus revenue estimates decrease by 13%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$76.0m to US$65.9m. EPS estimate increased from -US$0.995 to -US$0.917 per share. Healthcare Services industry in the US expected to see average net income growth of 26% next year. Consensus price target down from US$8.00 to US$6.00. Share price fell 23% to US$3.19 over the past week. Recent Insider Transactions Derivative • Aug 11
Independent Non-Executive Director notifies of intention to sell stock Kathy Hibbs intends to sell 16k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of August. If the sale is conducted around the recent share price of US$3.36, it would amount to US$53k. Since March 2024, Kathy has owned 37.41k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Price Target Changed • Aug 07
Price target decreased by 25% to US$6.00 Down from US$8.00, the current price target is an average from 4 analysts. New target price is 64% above last closing price of US$3.65. Stock is up 1.1% over the past year. The company is forecast to post a net loss per share of US$0.92 next year compared to a net loss per share of US$1.22 last year. Duyuru • Aug 06
SOPHiA GENETICS SA Provides Earnings Guidance for the Year 2024 SOPHiA GENETICS SA provided earnings guidance for the year 2024. For the period, the company Full-year revenue is now expected to be between $65 million and $67 million, representing growth of 4% to 7% compared to Fiscal Year 2023. Duyuru • Jul 23
SOPHiA GENETICS SA to Report Q2, 2024 Results on Aug 06, 2024 SOPHiA GENETICS SA announced that they will report Q2, 2024 results Pre-Market on Aug 06, 2024 Recent Insider Transactions Derivative • Jul 08
Co-Founder notifies of intention to sell stock Jurgi Camblong intends to sell 22k shares in the next 90 days after lodging an Intent To Sell Form on the 5th of July. If the sale is conducted around the recent share price of US$4.66, it would amount to US$103k. Since March 2024, Jurgi has owned 2.46m shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Board Change • Jul 05
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Independent Director Jean-Michel Yves Cossery was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Jun 24
Sophia Genetics S. A. Launches New Residual Acute Myeloid Application Sophia Genetics S.A. announced its new Residual Acute Myeloid (RAM) Application. The new offering expands the company's comprehensive oncology portfolio to support measurable residual disease (MRD) capabilities and will be available to customers worldwide this summer. Acute Myeloid Leukemia (AML) represents about one percent of all cancers worldwide, yet is one of the most common forms of leukemia in adults1. Over 50 percent of AML patients relapse within 3 years after achieving complete remission2, therefore post-treatment monitoring is imperative for AML patients, particularly within the first two years, to help quickly detect any signs of relapse3. MRD solutions can help inform post-remission therapy and identify early relapse, and serve as a primary endpoint in clinical trials, helping researchers detect even the smallest trace of cancer and support better patient outcomes. Next-generation sequencing (NGS)-based MRD testing is among the most advanced in cancer screening and monitoring, and can be found only with highly sensitive methods. The SOPHiA DDM™ RAM Solution provides users with the confidence that MRD will detect even one cancer cell among 10,000 cells. This application will allow users to stay ahead of disease response with the analytical capabilities of the SOPHiA DDM™ Platform, enabling sensitive variant detection down to 0.01% VAF and covering guideline-recommended genes to deliver robust insights for residual acute myeloid. Customers using the SOPHiA DDM™ RAM Solution will have access to longitudinal variant monitoring, allowing them to visualize the mutational landscape for each patient and its evolution over time. The solution also provides users with the most up-to-date databases and customizable reporting features to generate graphical representations and comprehensive MRD reports. Additionally, the SOPHiA DDM™ RAM Solution will continually hone its machine learning algorithms to provide the most accurate MRD results in just four days. Recent Insider Transactions Derivative • Jun 16
Executive VP notifies of intention to sell stock Philippe Menu intends to sell 33k shares in the next 90 days after lodging an Intent To Sell Form on the 13th of June. If the sale is conducted around the recent share price of US$4.80, it would amount to US$158k. Since March 2024, Philippe has owned 41.75k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Recent Insider Transactions Derivative • May 31
Executive VP & Chief Scientific Officer notifies of intention to sell stock Zhenyu Xu intends to sell 12k shares in the next 90 days after lodging an Intent To Sell Form on the 29th of May. If the sale is conducted around the recent share price of US$4.92, it would amount to US$59k. Since March 2024, Zhenyu has owned 414.25k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Duyuru • May 19
SOPHiA GENETICS SA, Annual General Meeting, Jun 24, 2024 SOPHiA GENETICS SA, Annual General Meeting, Jun 24, 2024, at 14:00 W. Europe Standard Time. Location: offices of sophia genetics sa, la piece 12, 1180 rolle vd, Switzerland Reported Earnings • May 08
First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.31 loss in 1Q 2023) First quarter 2024 results: US$0.21 loss per share (improved from US$0.31 loss in 1Q 2023). Revenue: US$15.8m (up 13% from 1Q 2023). Net loss: US$13.7m (loss narrowed 30% from 1Q 2023). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Duyuru • May 08
SOPHiA GENETICS Reiterates Earnings Guidance for the Full Year 2024 SOPHiA GENETICS reiterated earnings guidance for the full year 2024. Based on information as of May 7, 2024, SOPHiA GENETICS is reaffirming previously provided guidance of: revenue between $78 million and $81 million, representing growth of 25% to 30% compared to full year 2023 revenue. Duyuru • Apr 24
SOPHiA GENETICS SA to Report Q1, 2024 Results on May 07, 2024 SOPHiA GENETICS SA announced that they will report Q1, 2024 results Pre-Market on May 07, 2024 Major Estimate Revision • Mar 12
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$82.1m to US$79.8m. Losses expected to increase from US$0.91 per share to US$1.01. Healthcare Services industry in the US expected to see average net income growth of 32% next year. Consensus price target up from US$8.33 to US$8.67. Share price fell 14% to US$4.85 over the past week. Price Target Changed • Mar 06
Price target increased by 8.3% to US$8.67 Up from US$8.00, the current price target is an average from 3 analysts. New target price is 73% above last closing price of US$5.01. Stock is up 63% over the past year. The company is forecast to post a net loss per share of US$0.94 next year compared to a net loss per share of US$1.22 last year. Duyuru • Mar 06
SOPHiA GENETICS SA Provides Earnings Guidance for 2024 SOPHiA GENETICS is provided earnings guidance for 2024. For the period, company expects Revenue between $78 million and $81 million, representing growth of 25% to 30% compared to full year 2023. Reported Earnings • Mar 06
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: US$1.22 loss per share (improved from US$1.36 loss in FY 2022). Revenue: US$62.4m (up 31% from FY 2022). Net loss: US$79.0m (loss narrowed 9.7% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.9%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. 
